Company Updates
Breath Biopsy
Owlstone Medical Closes $58 Million USD (c. £42 Million GBP) Oversubscribed Financing Round to Continue to Advance Breath Biopsy
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, today announced the close of its Series D financing round, securing $58 million and bringing the total raised by the company to over $150 million since founding in 2016.
COVID-19
Owlstone Medical Publishes Data on the Use of Face Mask Filters to Capture Viral Particles for SARS-CoV-2 Detection
Breath Biopsy
Owlstone Medical Launches Breath Testing for Digestive Health in Collaboration with Functional Gut Diagnostics and Functional Gut Clinic
Breath Biopsy
Owlstone Medical Introduces Breath Biopsy Panel for Respiratory Diseases
Company Updates
Owlstone Medical Expands U.S. Operations and Establishes Permanent U.S. Office
Breath Biopsy
Owlstone Medical Announces Key Study Results on use of Breath Biopsy for Improved Detection of Liver Disease including NASH and NAFLD
Breath Biopsy
DRAGON: A new international project funded by IMI and supported through the European Commission’s Horizon 2020 Framework Programme for Research and Innovation to develop a diagnostics tool combatting coronavirus infections.
Company Updates
Owlstone Medical Appoints Neil Tween as Chief Financial Officer
Company Updates
Owlstone Medical named as one of FierceMedTech’s “Fierce 15” companies of 2019
Breath Biopsy
Owlstone Medical to Join EU-Funded EPHOR Consortium to Advance Occupational Health Science in Order to Reduce Disease Burden from Workplace Exposure
Breath Biopsy
Owlstone Medical Enters Partnership with Thermo Fisher Scientific to Advance Early Disease Detection Using Non-Invasive Breath Biopsy
Breath Biopsy
Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases
